RDUS Radius Health Inc.

18.69
-0.16  -1%
Previous Close 18.85
Open 18.43
Price To Book -35.26
Market Cap 862,961,334
Shares 46,172,356
Volume 115,639
Short Ratio
Av. Daily Volume 543,472
Stock charts supplied by TradingView

NewsSee all news

  1. Radius Exceeds 2019 Financial Guidance and Provides Business Update at the 38th Annual J.P. Morgan Healthcare Conference

    Full-Year 2019 TYMLOS U.S. net revenue exceeds financial guidance, surpassing $172M. TYMLOS exits 2019 with 52% market share in new patients1, on track for market leadership in 2020. Radius delivers strong year-end

  2. Radius Health to Present at the 38th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ:RDUS), today announced that its senior executive management team will present a corporate update at the 38th Annual J.P. Morgan Healthcare

  3. Radius Health Announces Scientific Presentations at 2019 San Antonio Breast Cancer Symposium (SABCS)

    WALTHAM, Mass., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ:RDUS) today announced its scientific presentations on elacestrant and RAD140 at the upcoming 2019 San Antonio

  4. Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ:RDUS) today announced that the Compensation Committee of the Company's Board of Directors granted a new employee

  5. Radius Health to Present at Jefferies 2019 Global Healthcare Conference in London

    WALTHAM, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ:RDUS), today announced that Jesper Hoeiland, President and CEO of the Company, will present a corporate update at the Jefferies 2019 Global

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial initiation announced March 31, 2018.
TYMLOS Abaloparatide-SC
Male Osteoporosis
Phase 3 enrolment to be completed 3Q 2020.
Elacestrant - EMERALD
Breast cancer
PDUFA date originally scheduled for March 30 2017 delayed by three months to June 30, 2017. Approval announced April 28, 2017.
TYMLOS (Abaloparatide)
Osteoporosis
Phase 1 dose-expansion cohort to be initiated mid-2019.
AB122
Solid tumors
Phase 3 data due 2H 2021.
Abaloparatide -Transdermal Patch
Osteoporosis
Phase 1 trial presentation at SABCS December 2018.
RAD140
Breast cancer

Latest News

  1. Radius Exceeds 2019 Financial Guidance and Provides Business Update at the 38th Annual J.P. Morgan Healthcare Conference

    Full-Year 2019 TYMLOS U.S. net revenue exceeds financial guidance, surpassing $172M. TYMLOS exits 2019 with 52% market share in new patients1, on track for market leadership in 2020. Radius delivers strong year-end

  2. Radius Health to Present at the 38th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ:RDUS), today announced that its senior executive management team will present a corporate update at the 38th Annual J.P. Morgan Healthcare

  3. Radius Health Announces Scientific Presentations at 2019 San Antonio Breast Cancer Symposium (SABCS)

    WALTHAM, Mass., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ:RDUS) today announced its scientific presentations on elacestrant and RAD140 at the upcoming 2019 San Antonio

  4. Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ:RDUS) today announced that the Compensation Committee of the Company's Board of Directors granted a new employee

  5. Radius Health to Present at Jefferies 2019 Global Healthcare Conference in London

    WALTHAM, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ:RDUS), today announced that Jesper Hoeiland, President and CEO of the Company, will present a corporate update at the Jefferies 2019 Global

  6. Radius Health Announces Third Quarter 2019 Results and Corporate Update

    TYMLOS U.S. net sales grew to $47M and is capturing half of anabolic new patient starts1 Guidance for FY 2019 sales increased to $168-$172M (vs. $165-$170M prior) and year-end cash, cash equivalents and investments

  7. Radius Health to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 5, 2019

    WALTHAM, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Radius Health (NASDAQ:RDUS) announced today that it will release its third quarter 2019 financial results on Tuesday, November 5, 2019. The Company will host a

  8. Radius Health to Present Data on Abaloparatide at ASBMR 2019 Annual Meeting

    WALTHAM, Mass., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ:RDUS), today announced it will present five posters, including results from a real-world study on patient experience, at the American

  9. Radius Health to Participate in the Citi 14th Annual Biotech Conference and Morgan Stanley 17th Annual Global Healthcare Conference in September

    WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ:RDUS) today announced its participation in the following conferences in September 2019. Radius Health management will host meetings with